Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, licensing, clinical development, and commercialization of therapies to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline products include eleven clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal, and infectious diseases. Everest Medicines Limited was incorporated in 2017...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E.
Target Price
The average target price of 1952.HK is 62 and suggests 72% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell